Highlights of This Issue  4491

SPECIAL FEATURES

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis
Michael L. Maitland
See article p. 4647

X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise
Hamid Kashkar

Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

DNA Repair: A Reinvigorated Therapeutic Target
Susan E. Bates

DNA Damage and Repair in Translational Oncology: An Overview
Eddie Reed

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata and Joyce O'Shaughnessy

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Ruth Plummer

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair
Dorine Rossetto, Andrew W. Truman, Stephen J. Kron, and Jacques Côté

"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
Norman Chan and Robert G. Bristow

Molecular Pathways

CCR Focus

DNA Repair: A Reinvigorated Therapeutic Target
Susan E. Bates

DNA Damage and Repair in Translational Oncology: An Overview
Eddie Reed

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata and Joyce O'Shaughnessy

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Ruth Plummer

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer

System-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma
Olena Morozova, Milijana Vojvodic, Natalie Grinshtein, Loen M. Hansford, Kim M. Blakely, Alexandra Maslova, Martin Hirst, Timothee Cezard, Ryan D. Morin, Richard Moore, Kristen M. Smith, Freda Miller, Paul Taylor, Nina Thiessen, Richard Varhol, Yongjiun Zhao, Steven Jones, Jason Moffat, Thomas Kislinger, Michael F. Moran, David R. Kaplan, and Marco A. Marra

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Kirthika N. Kodumudi, Karrune Woan, Danielle L. Gilvary, Eva Sahakian, Sheng Wei, and Julie Y. Djeu

Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice
Kameswaran Ravichandran, Balaiya Velmurugan, Mallikarjuna Gu, Rana P. Singh, and Rajesh Agarwal

HUMAN CANCER BIOLOGY

CANCER THERAPY: PRECLINICAL
**IMAGING, DIAGNOSIS, PROGNOSIS**

4607  Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers
Maha Ayyoub, Pascale Pignon, Danijel Dojcinovic, Isabelle Raimbaud, Lloyd I. Old, Immanuel Luescher, and Danila Valmori

4616  Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

4625  Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients
Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hideshi Ishii, Fumio Tanaka, Tsuyoshi Nakagawa, Takahiro Kato, Shinji Ono, Kenichi Sugiura, and Masaki Mori

4636  Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells
Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takemasa, Koshi Mimori, Hideyuki Henni, Tsuneaki Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsur, Yuichiro Koki, and Masaki Mori

4647  A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzheng Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, and Lawrence H. Schwartz
See commentary p. 4493

**CANCER THERAPY: CLINICAL**

4654  Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor 1 Receptor Inhibition

4666  An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

4675  Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists
Stephen V. Liu, Andrew V. Schally, Debra Hawes, Shigang Xiong, Laden Fazli, Martin Gleave, Jie Cai, Susan Groshen, Frank Brands, Juergen Engel, and Jacek Pinski

4681  Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1, Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies
See commentary p. 4493
ABOUT THE COVER

Clinical Use of γH2AX and PAR: Image of an anagen hair bulb plucked from the scalp of a cancer patient 24 hours after drug infusion. γH2AX antibody reveals DNA double-strand breaks (green foci) in cell nuclei (red). Imaged using a Nikon PCM 2000 laser scanning confocal microscope. For details, please see the article by Redon and colleagues on p. 4532 of this issue.